Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pre-formulation is a precursor to more in-depth formulation development, however it is also a powerful screening tool that can be utilized during candidate ranking as part of the lead selection stage. Pre-formulation can be applied at the early stages of drug development programs to help determine the fundamental properties of biotherapeutic drug candidates. This approach can de-risk programs through the use of clear developability assessments, and can cut down on costly trials by identifying in the very early stages any inherent liabilities. This ultimately allows for selection of the best candidates for the next development stage.
In this webinar, Gary Watts, Senior Scientist at Abzena describes:
Senior Scientist
Abzena
Gary Watts is a Senior Scientist within the Analytics Group at Abzena and is currently leading the pre-formulation and formulation development departments. He has over 5 years’ experience in formulation and the analysis of biologics, as well as leading formulation studies covering early-stage and late-stage development.
Gary has a wealth of experience partnering with clients to establish optimal formulations for the required administration route, including very high-concentration products, and has worked with peptides, antibodies, vaccines, and novel antibody formats such as fusion proteins and multi-specific antibodies. He is also a co-inventor on two formulation patents and holds a PhD in Organic Chemistry from the University of East Anglia.
Andrea Charles
Custom Content Editor
Informa Pharma Intelligence
By completing this form you agree Abzena may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.